Form 4 for SRPT Sarepta Therapeutics, Inc.
Accepted 2024-03-05 00:00:00 ET · period of report 2024-03-01 · accession 0000950170-24-026617 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-03-05 | 2024-03-01 | SRPT | Nicaise Claude | Dir | A - Grant | $0.00 | +1,846 | 18.2K | +11% | $0 |
| D | 2024-03-05 | 2024-03-01 | SRPT | Nicaise Claude | Dir | A - Grant | $0.00 | +3,679 | 3,679 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-03-01 | A | A | 1,846 | $0.00 | 18,174 | D | — | — | (F1) The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 1, 2025. |
| 2 | Derivative | Stock Option (right to buy) | 2024-03-01 | A | A | 3,679 | $0.00 | 3,679 | D | $128.67 · 2025-03-01 to 2034-03-01 | 3,679 Common Stock |